Explain this page
Arphra AIPlain-English read on Eli Lilly and Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.60% | -2.90% | +10.54% | +4.60% | +1.79% | -0.92% | +42.53% | +140.73% | +434.75% | +1311.13% | +37794.66% |
Aftermarket
LiveLast trade
$1066.22
110 sh
Bid
$1065.00
120 sh
Ask
$1067.00
6 sh
Spread
$2.000
Sector & industry today
LiveSectors
- Technology+1.60%
- Industrials+1.51%
- Energy+1.40%
- Basic Materials+1.37%
- Utilities+0.94%
- Consumer Cyclical+0.47%
- Real Estate+0.38%
- Consumer Defensive+0.29%
- Financial Services+0.05%
- Healthcare-0.25%
- Communication Services-0.38%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General+0.23%
- Electronic Gaming & Multimedia-5.14%
- Hardware, Equipment & Parts+4.56%
- Real Estate - Services+4.51%
- REIT - Office+4.46%
- Computer Hardware-4.35%
- Agricultural - Machinery+3.56%
- Information Technology Services+3.39%
- Auto - Parts+3.38%
- Oil & Gas Energy+3.12%
- Communication Equipment+2.94%
- Solar+2.91%
Fair value
Football field →Weighted blend
$2,670.53
+150.79% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
2bull14bear
±5% threshold
Analyst PT consensus: $1,258.47 (+18.18%)
Total assets
$112.48B
Total debt
$42.5B
Cash & equiv
$7.16B
Operating CF
$16.81B
Free cash flow
$8.97B
Buybacks
-$4.11B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$1,258.47
+18.18% upside
Low
$1,070.00
Median
$1,280.00
High
$1,350.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Eli Lilly launches Alzheimer's drug Donanemab in Indiareuters.com·May 13, 2026
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsprnewswire.com·May 12, 2026
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsprnewswire.com·May 12, 2026
- Is It Too Late to Buy Eli Lilly and Co (LLY) After 4.4% Rally? GF Value Says Undervaluedgurufocus.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesgurufocus.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesprnewswire.com·May 12, 2026
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesprnewswire.com·May 12, 2026
- Eli Lilly Price Prediction: This Is Where The Stock Will End This Year247wallst.com·May 12, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.8B | $7.4B | $8.26 |
| Q4 Dec 2025 | $19.29B | $6.64B | $7.39 |
| Q3 Sep 2025 | $17.6B | $5.58B | $6.21 |
| Q2 Jun 2025 | $15.56B | $5.66B | $6.29 |
| Q1 Mar 2025 | $12.73B | $2.76B | $3.06 |
| Q4 Dec 2024 | $13.53B | $4.41B | $4.88 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 2,208 | $2.2M | May 06, 2026 |
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 13,620 | $13.55M | May 06, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,070 | $1.16M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,322 | $1.45M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 895 | $971.17K | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 930 | $1.01M | Jan 07, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $65.18B | $29.7B | $20.64B | $22.95 | +31.66% |
| FY 2024 | $45.04B | $17.5B | $10.59B | $11.71 | +23.51% |
| FY 2023 | $34.12B | $10.79B | $5.24B | $5.80 | +15.36% |
| FY 2022 | $28.54B | $8.65B | $6.24B | $6.57 | +21.88% |
| FY 2021 | $28.32B | $7.93B | $5.58B | $5.85 | +19.71% |